zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2011-8-4-10zdor-1157Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEРЕЗУЛЬТАТЫ ПРИМЕНЕНИЯ ГЕМОПОЭТИЧЕСКИХ ФАКТОРОВ РОСТА ПОСЛЕ ВЫСОКОДОЗНОЙ ХИМИОТЕРАПИИ С ТРАНСПЛАНТАЦИЕЙ СТВОЛОВЫХ ГЕМОПОЭТИЧЕСКИХ КЛЕТОКRESULTS OF THE APPLICATION OF HAEMOPOIETIC GROWTH FACTORS AFTER HIGH DOSE CHEMOTHERAPY WITH TRANSPLANTATION OF HAEMOPOIETIC STEM CELLSКузьмичЕ. А.KuzmichE. A.noemail@neicon.ruЗмачинскийВ. А.ZmachinskiyV. A.noemail@neicon.ruРеспубликанский научно-практический центр гематологии и трансфузиологии, г. МинскRepublican Research Center for Hematology and Transfusiology, MinskБелорусская медицинская академия последипломного образования, г. МинскBelarussian Medical Academy for Postgraduate Education, Minsk201128122011046266Copyright © Кузьмич Е.А., Змачинский В.А., 20112011Кузьмич Е.А., Змачинский В.А.Kuzmich E.A., Zmachinskiy V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1157

В статье приведены ранние и долгосрочные результаты сочетанного применения гемопоэтических факторов роста - эритропоэтина и гранулоцитарного колониестимулирующего фактора после высокодозной химиотерапии с трансплантацией стволовых гемопоэтических клеток у пациентов с гематологическими и онкогематологическими заболеваниями. Установлено, что сочетанная терапия гемопоэтическими факторами роста у пациентов после аллогенной трансплантации стволовых гемопоэтических клеток приводит к улучшению приживления донорского костного мозга. Получено уменьшение средней длительности пребывания в стационаре в посттрансплантационном периоде, а также увеличение показателей вероятностной 5-летней безрецидивной выживаемости пациентов с лимфомой Ходжкина, пролеченных сочетанием эритропоэтина и гранулоцитарного колониестимулирующего фактора.

The article presents early and long-term results of the combined application of haemopoetic growth factors, i.e. erythropoietin and granulocyte colony-stimulating factor after high-dose chemotherapy with haemopoetic stem cell transplantation in patients with hematologic and oncohematologic disorders. It has been established that the combined therapy with haemopoetic growth factors after the allogeneic transplantation of haemopoetic stem cell leads to better donor marrow engraftment. This reduces the average patients` stay at hospital in the posttransplantation period and increases the indicators of 5-year-old non-relapsing survival rate of patients with Hodzhkin`s lymphoma treated with a combination of erythropoietin and granulocyte colony-stimulating factor.

трансплантация стволовых гемопоэтических клетокгемопоэтические факторы ростаэритроцитарный химеризмсроки госпитализациивыживаемостьtransplantation of haemopoietic stem cellshaemopoietic growth factorserythrocyte chimerahospitalization termssurvival rateReferencesIntensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma / R. Abraham [et al.] // Bone Marrow Transplant. - 1999. - Vol. 94. - P. 1291-1297.Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma / R. Abraham [et al.] // Bone Marrow Transplant. - 1999. - Vol. 94. - P. 1291-1297.Regimen-related toxicity in patients undergoing bone marrow transplantation / S. Bearman [et al.] // Journal of Clinical Oncology. - 1988. - Vol. 6. - P. 1562-1568.Regimen-related toxicity in patients undergoing bone marrow transplantation / S. Bearman [et al.] // Journal of Clinical Oncology. - 1988. - Vol. 6. - P. 1562-1568.High dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (> 65 years) myeloma patients: comparison with younger patients treated on the same protocol / E. Jantunen [et al.] // Bone Marrow Transplant. - 2006. - Vol. 107. - P. 917-922.High dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (> 65 years) myeloma patients: comparison with younger patients treated on the same protocol / E. Jantunen [et al.] // Bone Marrow Transplant. - 2006. - Vol. 107. - P. 917-922.A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease / J. A. Glaspy [et al.] // Cancer. - 2003. - Vol. 97. - P. 1312-1320.A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease / J. A. Glaspy [et al.] // Cancer. - 2003. - Vol. 97. - P. 1312-1320.Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha / M. McColl [et al.] // J. Exp. Med. - 1992. - Vol. 176. - P. 593-598.Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha / M. McColl [et al.] // J. Exp. Med. - 1992. - Vol. 176. - P. 593-598.Белогурова, М. Б. Клиническое использование гемопоэтических ростовых факторов / М. Б. Белогурова // Практическая онкология. - 2003. - Т. 4, № 3 - С. 183-190.Белогурова, М. Б. Клиническое использование гемопоэтических ростовых факторов / М. Б. Белогурова // Практическая онкология. - 2003. - Т. 4, № 3 - С. 183-190.The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone / N. Flomenberg [et al.] // Blood. - 2005. -Vol. 106. - P. 1867-1874.The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone / N. Flomenberg [et al.] // Blood. - 2005. -Vol. 106. - P. 1867-1874.Pusic, I. The Use of Growth Factors in Hematopoietic Stem Cell Transplantation / I. Pusic, J. F. DiPersio // Current Pharmaceutical Design. - 2008. - Vol. 14. - P. 1950-1961.Pusic, I. The Use of Growth Factors in Hematopoietic Stem Cell Transplantation / I. Pusic, J. F. DiPersio // Current Pharmaceutical Design. - 2008. - Vol. 14. - P. 1950-1961.Addition of erythrpoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hematopoietic progenitor mobilization / A. Olivieri [et al.] // Bone Marrow Transplantation. - 1995. - Vol. 16. - P. 765-770.Addition of erythrpoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hematopoietic progenitor mobilization / A. Olivieri [et al.] // Bone Marrow Transplantation. - 1995. - Vol. 16. - P. 765-770.EPO in combination with G-CSF improves mobilization effectivness after chemotherapy with ifosfamide, epirubicin, and etoposide and reduces costs during mobilization and transplantation of autulogous hematopoietic progenitor cells / C. Hart [et al.] // Bone Marrow Transplantation. - 2009. - Vol. 43(3). - P. 197-206.EPO in combination with G-CSF improves mobilization effectivness after chemotherapy with ifosfamide, epirubicin, and etoposide and reduces costs during mobilization and transplantation of autulogous hematopoietic progenitor cells / C. Hart [et al.] // Bone Marrow Transplantation. - 2009. - Vol. 43(3). - P. 197-206.Kaushansky, K. Lineage-specific hematopoietic growth factors / K. Kaushansky // N Engl J Med. - 2006. - Vol. 354. - P. 2034-2045.Kaushansky, K. Lineage-specific hematopoietic growth factors / K. Kaushansky // N Engl J Med. - 2006. - Vol. 354. - P. 2034-2045.

The authors declare that there are no conflicts of interest present.